The IMPROVE™ study - a multinational, multicentre, observational study in type 2 diabetes: Results from the Italian cohort

Carlo Giorda, Massimo Boemi, Vito Borzì, Francesco Chiaramonte, Paola Mattei, Antonino Tribulato

Research output: Contribution to journalArticle

Abstract

Aims: The IMPROVE™ study evaluated the safety and effectiveness of biphasic insulin aspart 30/70 (BIAsp 30) in type 2 diabetes patients in the routine practice. Here we present the results for patients from Italy. Methods: Adverse events, hypoglycaemia, glycaemic control, patient treatment satisfaction and physician resource utilisation were assessed at baseline and 26 weeks. Results: Out of the 1371 patients enrolled, 84.1% (n = 1153) were receiving BIAsp 30 at baseline (in accordance with local regulations), and were included in the study. Mean HbA 1c reduction was -0.63% after 26 weeks (p <0.001); 26.5% and 13.5% of patients reached the HbA 1c targets of

Original languageEnglish
Pages (from-to)115-124
Number of pages10
JournalActa Biomedica
Volume81
Issue number2
Publication statusPublished - 2010

Keywords

  • Biphasic insulin aspart
  • Glycaemic control
  • HbA1c
  • Hypoglycaemia
  • Type 2 diabetes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The IMPROVE™ study - a multinational, multicentre, observational study in type 2 diabetes: Results from the Italian cohort'. Together they form a unique fingerprint.

  • Cite this

    Giorda, C., Boemi, M., Borzì, V., Chiaramonte, F., Mattei, P., & Tribulato, A. (2010). The IMPROVE™ study - a multinational, multicentre, observational study in type 2 diabetes: Results from the Italian cohort. Acta Biomedica, 81(2), 115-124.